Loading...

Soleno Therapeutics

BST:6XC1
Snowflake Description

Flawless balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
6XC1
BST
$64M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Soleno Therapeutics, Inc. focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. The last earnings update was 27 days ago. More info.


Add to Portfolio Compare Print
  • Soleno Therapeutics has significant price volatility in the past 3 months.
6XC1 Share Price and Events
7 Day Returns
3.5%
BST:6XC1
0.4%
DE Biotechs
0.8%
DE Market
1 Year Returns
30%
BST:6XC1
-5.6%
DE Biotechs
-4.5%
DE Market
6XC1 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Soleno Therapeutics (6XC1) 3.5% -10.2% 23.5% 30% -66.9% -
DE Biotechs 0.4% 7.3% -6.5% -5.6% 51.9% 10.5%
DE Market 0.8% 6.9% 8.1% -4.5% 10.4% 13.9%
1 Year Return vs Industry and Market
  • 6XC1 outperformed the Biotechs industry which returned -5.6% over the past year.
  • 6XC1 outperformed the Market in Germany which returned -4.5% over the past year.
Price Volatility
6XC1
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Soleno Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Soleno Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is €1.7414.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Soleno Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Soleno Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BST:6XC1 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.56
NasdaqCM:SLNO Share Price ** NasdaqCM (2019-04-25) in USD $2.01
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.58x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 20.1x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Soleno Therapeutics.

BST:6XC1 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:SLNO Share Price ÷ EPS (both in USD)

= 2.01 ÷ -0.56

-3.56x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Soleno Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Soleno Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Soleno Therapeutics's expected growth come at a high price?
Raw Data
BST:6XC1 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -3.56x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
57.2%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.33x
Germany Market PEG Ratio Median Figure of 268 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Soleno Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Soleno Therapeutics's assets?
Raw Data
BST:6XC1 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.96
NasdaqCM:SLNO Share Price * NasdaqCM (2019-04-25) in USD $2.01
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.83x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
BST:6XC1 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:SLNO Share Price ÷ Book Value per Share (both in USD)

= 2.01 ÷ 0.96

2.1x

* Primary Listing of Soleno Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Soleno Therapeutics is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Soleno Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Soleno Therapeutics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Soleno Therapeutics expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
57.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Soleno Therapeutics expected to grow at an attractive rate?
  • Soleno Therapeutics's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Soleno Therapeutics's earnings growth is expected to exceed the Germany market average.
  • Unable to compare Soleno Therapeutics's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
BST:6XC1 Future Growth Rates Data Sources
Data Point Source Value (per year)
BST:6XC1 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 57.2%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.8%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BST:6XC1 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BST:6XC1 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 250 165 1
2022-12-31 80 7 1
2021-12-31 19 -38 1
2020-12-31 0 -50 1
2019-12-31 0 -33 1
BST:6XC1 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -12 -12
2018-09-30 -11 -17
2018-06-30 -10 -17
2018-03-31 -10 -13
2017-12-31 -10 -12
2017-09-30 -10 -13
2017-06-30 0 -11 -11
2017-03-31 0 -12 -9
2016-12-31 -13 -10
2016-09-30 0 -14 -8
2016-06-30 0 -14 -10
2016-03-31 1 -12 -7

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Soleno Therapeutics's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Soleno Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BST:6XC1 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Soleno Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:6XC1 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 3.97 3.97 3.97 1.00
2022-12-31 0.18 0.18 0.18 1.00
2021-12-31 -0.96 -0.96 -0.96 1.00
2020-12-31 -1.34 -1.34 -1.34 1.00
2019-12-31 -1.10 -1.10 -1.10 1.00
BST:6XC1 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.56
2018-09-30 -0.92
2018-06-30 -1.14
2018-03-31 -1.05
2017-12-31 -1.31
2017-09-30 -1.84
2017-06-30 -2.13
2017-03-31 -2.54
2016-12-31 -3.35
2016-09-30 -2.75
2016-06-30 -3.91
2016-03-31 -3.27

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Soleno Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Soleno Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Soleno Therapeutics has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Soleno Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Soleno Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Soleno Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Soleno Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Soleno Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Soleno Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Soleno Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:6XC1 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -11.84 6.56 7.18
2018-09-30 -16.71 6.88 6.01
2018-06-30 -17.43 7.00 4.86
2018-03-31 -13.27 7.43 3.92
2017-12-31 -11.79 6.61 3.07
2017-09-30 -12.67 6.30 2.33
2017-06-30 0.00 -11.15 5.51 1.72
2017-03-31 -0.45 -9.24 4.47 0.80
2016-12-31 -10.39 5.90 2.25
2016-09-30 0.24 -8.16 6.74 3.24
2016-06-30 0.49 -10.48 8.02 4.10
2016-03-31 1.03 -7.45 8.80 5.43
2015-12-31 -9.74 5.99
2015-09-30 0.37 -20.28 6.73 4.04
2015-06-30 0.12 -19.38 5.22 3.50
2015-03-31 0.02 -24.05 4.16 2.75
2014-12-31 -13.24 2.92 2.24
2014-09-30 0.00 -6.99 1.82 2.05
2014-06-30 0.00 -6.19 1.64 1.90
2014-03-31 0.00 -5.56 1.36 2.05
2013-12-31 3.00 -3.71 1.47 2.38
2012-12-31 -6.48 1.13 2.47

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Soleno Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Soleno Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Soleno Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Soleno Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Soleno Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Soleno Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Soleno Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Soleno Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Soleno Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Soleno Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Soleno Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Soleno Therapeutics Company Filings, last reported 3 months ago.

BST:6XC1 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 30.41 0.00 24.08
2018-09-30 14.21 0.00 10.24
2018-06-30 15.84 0.00 12.59
2018-03-31 23.02 0.00 14.87
2017-12-31 26.82 0.00 17.10
2017-09-30 23.21 0.00 5.65
2017-06-30 26.69 0.00 7.55
2017-03-31 30.14 0.00 10.54
2016-12-31 3.44 0.00 2.73
2016-09-30 5.71 0.00 5.42
2016-06-30 2.61 0.00 2.50
2016-03-31 5.83 0.00 6.49
2015-12-31 3.22 0.00 5.49
2015-09-30 -1.29 0.00 4.72
2015-06-30 -7.63 0.00 7.53
2015-03-31 -11.30 0.00 9.53
2014-12-31 -11.19 0.10 7.96
2014-09-30 -15.50 15.60 0.06
2014-06-30 1.17 0.00 1.21
2014-03-31 -13.66 14.38 0.76
2013-12-31 -12.59 13.99 1.27
2012-12-31 -9.03 11.13 2.16
  • Soleno Therapeutics has no debt.
  • Soleno Therapeutics currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Soleno Therapeutics has sufficient cash runway for 2.1 years based on current free cash flow.
  • Soleno Therapeutics has sufficient cash runway for 2.2 years if free cash flow continues to reduce at historical rates of -7.9% each year.
X
Financial health checks
We assess Soleno Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Soleno Therapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Soleno Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Soleno Therapeutics dividends.
If you bought €2,000 of Soleno Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Soleno Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Soleno Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BST:6XC1 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BST:6XC1 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Soleno Therapeutics has not reported any payouts.
  • Unable to verify if Soleno Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Soleno Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Soleno Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Soleno Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Soleno Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Soleno Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Soleno Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Anish Bhatnagar
COMPENSATION $1,288,000
AGE 48
TENURE AS CEO 5.2 years
CEO Bio

Dr. Anish Bhatnagar, M.D. has been the Chief Executive Officer of Soleno Therapeutics, Inc. since February 6, 2014, President since December 31, 2013. Dr. Bhatnagar has been Director at Soleno Therapeutics, Inc. since February 02, 2014. Dr. Bhatnagar served as the Chief Operating Officer of Capnia, Inc. and served as its Chief Medical Officer of Clinical & Regulatory. He served as Senior Vice President of Clinical & Regulatory of Capnia Inc. He is a physician with over 15 years of clinical and regulatory experience in the biopharmaceutical and medical device industry. His experience spans development of biologics, drugs, drug-device combinations and medical devices. He has extensive experience in the pharmaceutical industry in all aspects of drug and device development from pre-IND to Phase III and Expanded Access as well as BLA submission. He has implemented clinical trials in neurology, psychiatry, pulmonary/allergy, cardiovascular disease, endocrine/metabolic disease and hematology/oncology in North America, South America, Asia, Africa as well as Western and Eastern Europe. He has been the lead in regulatory interactions with several divisions at the FDA and international regulatory authorities (such as those in the UK, France, Australia and Sweden). He joined Capnia, Inc. since 2006. His experience includes working at Coulter Pharmaceuticals, Inc. 1998 to 2000 and Titan Pharmaceuticals from 2000 to 2006 at increasing levels of responsibility. He is the author of several peer-reviewed publications, abstracts and book chapters. He completed his Residency and Fellowship training at Georgetown University Hospital and the University of Pennsylvania. He obtained his medical degree at SMS Medical College in Jaipur, India.

CEO Compensation
  • Anish's compensation has increased whilst company is loss making.
  • Anish's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Soleno Therapeutics management team in years:

2.9
Average Tenure
57.5
Average Age
  • The tenure for the Soleno Therapeutics management team is about average.
Management Team

Anish Bhatnagar

TITLE
President
COMPENSATION
$1M
AGE
48
TENURE
5.2 yrs

Tony Wondka

TITLE
Senior Vice President of Research & Development
COMPENSATION
$270K
AGE
56
TENURE
4.3 yrs

David O'Toole

TITLE
Consultant
COMPENSATION
$358K
AGE
59
TENURE
1.6 yrs

Jon Wolter

TITLE
CFO & Principal Accounting Officer
AGE
68
TENURE
1.6 yrs

Neil Cowen

TITLE
Senior Vice President of Drug Development

Patricia Hirano

TITLE
Head of Regulatory Affairs and Quality
Board of Directors Tenure

Average tenure and age of the Soleno Therapeutics board of directors in years:

4.8
Average Tenure
60
Average Age
  • The tenure for the Soleno Therapeutics board of directors is about average.
Board of Directors

Ernie Mario

TITLE
Chairman
COMPENSATION
$80K
AGE
79
TENURE
5.2 yrs

Anish Bhatnagar

TITLE
President
COMPENSATION
$1M
AGE
48
TENURE
5.2 yrs

Bill Harris

TITLE
Independent Director
COMPENSATION
$75K
AGE
60
TENURE
4.8 yrs

Mahendra Shah

TITLE
Director
COMPENSATION
$53K
AGE
73
TENURE
2.1 yrs

Andrew Sinclair

TITLE
Director
AGE
46
TENURE
0.3 yrs

Thomas Casale

TITLE
Member of Advisory Board

Glenis Scadding

TITLE
Member of Advisory Board

David Stevenson

TITLE
Member of Advisory Board

Vinny Bhutani

TITLE
Member of Advisory Board

Robert Christensen

TITLE
Member of Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
18. Mar 19 Buy Oracle Investment Management, Inc. Company 14. Mar 19 14. Mar 19 130,363 €1.08 €141,030
27. Dec 18 Buy Abingworth LLP Company 21. Dec 18 21. Dec 18 4,669,272 €1.40 €6,545,946
27. Dec 18 Buy Jack Schuler Individual 21. Dec 18 21. Dec 18 3,031,002 €1.41 €4,265,954
21. Dec 18 Buy Oracle Investment Management, Inc. Company 19. Dec 18 19. Dec 18 1,245,135 €1.41 €1,750,453
14. Sep 18 Sell Technology Partners Company 11. Sep 18 13. Sep 18 -22,682 €1.75 €-39,461
16. May 18 Buy Oracle Investment Management, Inc. Company 14. May 18 15. May 18 50,000 €1.62 €75,667
X
Management checks
We assess Soleno Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Soleno Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Soleno Therapeutics, Inc. focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate, diazoxide choline controlled-release (DCCR), a tablet for the treatment of Prader-Willi Syndrome (PWS), is entering into late-stage clinical development. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was founded in 1999 and is based in Redwood City, California.

Details
Name: Soleno Therapeutics, Inc.
6XC1
Exchange: BST
Founded: 1999
$57,304,679
31,755,169
Website: http://www.soleno.life
Address: Soleno Therapeutics, Inc.
1235 Radio Road,
Suite 110,
Redwood City,
California, 94065,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM SLNO Common Stock Nasdaq Capital Market US USD 14. Nov 2014
BST 6XC1 Common Stock Boerse-Stuttgart DE EUR 14. Nov 2014
Number of employees
Current staff
Staff numbers
9
Soleno Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/25 22:37
End of day share price update: 2019/04/25 00:00
Last estimates confirmation: 2019/03/18
Last earnings filing: 2019/03/29
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.